As regards the field of HCC, around 10% of tumor cells have been suggested to express PD-L1, with this biomarker reporting a putative prognostic value (38); in particular, PD-L1 positive HCCs have been associated with shorter survival and recurrence-free survival, with recent retrospective trials reporting a possible link between macrovascular invasion, poorly differentiated or undifferentiated disease, high serum alfa-fetoprotein (AFP), and PD-L1 expression (39). The gene discussed is CD274; the disease is hepatocellular carcinoma.